This study evaluates the cost-effectiveness of annual MRI and mammography screening for breast cancer in BRCA1/2 mutation carriers in British Columbia, Canada. The incremental cost-effectiveness ratio for combined MRI and mammography compared to mammography alone was found to be $50,900 per quality-adjusted life-year (QALY), indicating that combined screening is potentially cost-effective under certain conditions. However, the effectiveness is sensitive to MRI costs, suggesting that higher MRI prices may compromise its cost-effectiveness.
Related topics: